Dabrafenib Mesylate Patent Expiration
Dabrafenib Mesylate is used for treating metastatic melanoma and anaplastic thyroid cancer with specific genetic mutations. It was first introduced by Novartis Pharmaceuticals Corp
Dabrafenib Mesylate Patents
Given below is the list of patents protecting Dabrafenib Mesylate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tafinlar |
US11504333 (Pediatric) | Pharmaceutical composition | Dec 29, 2038 | Novartis |
| Tafinlar | US11504333 | Pharmaceutical composition | Jun 29, 2038 | Novartis |
| Tafinlar |
US10869869 (Pediatric) | Method of adjuvant cancer treatment | Feb 28, 2034 | Novartis |
| Tafinlar | US10869869 | Method of adjuvant cancer treatment | Aug 30, 2033 | Novartis |
| Tafinlar |
US8703781 (Pediatric) | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Apr 15, 2031 | Novartis |
| Tafinlar |
US8952018 (Pediatric) | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Apr 15, 2031 | Novartis |
| Tafinlar | US8703781 | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors | Oct 15, 2030 | Novartis |
| Tafinlar | US8952018 | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors | Oct 15, 2030 | Novartis |
| Tafinlar |
US7994185 (Pediatric) | Benzene sulfonamide thiazole and oxazole compounds | Jul 20, 2030 | Novartis |
| Tafinlar |
US8415345 (Pediatric) | Benzene sulfonamide thiazole and oxazole compounds | Jul 20, 2030 | Novartis |
| Tafinlar | US7994185 | Benzene sulfonamide thiazole and oxazole compounds | Jan 20, 2030 | Novartis |
| Tafinlar | US8415345 | Benzene sulfonamide thiazole and oxazole compounds | Jan 20, 2030 | Novartis |
| Tafinlar |
US9233956 (Pediatric) | Benzene sulfonamide thiazole and oxazole compounds | Nov 04, 2029 | Novartis |
| Tafinlar | US9233956 | Benzene sulfonamide thiazole and oxazole compounds | May 04, 2029 | Novartis |
| Tafinlar |
US8835443 (Pediatric) | Pyrimidine compound and medical use thereof |
Dec 10, 2025
(Expired) | Novartis |
| Tafinlar | US8835443 | Pyrimidine compound and medical use thereof |
Jun 10, 2025
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Dabrafenib Mesylate's patents.
Latest Legal Activities on Dabrafenib Mesylate's Patents
Given below is the list recent legal activities going on the following patents of Dabrafenib Mesylate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Sep, 2024 | US8415345 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 28 Jun, 2023 | US9233956 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jan, 2023 | US7994185 |
| Patent Issue Date Used in PTA Calculation Critical
| 22 Nov, 2022 | US11504333 |
| Recordation of Patent Grant Mailed Critical
| 22 Nov, 2022 | US11504333 |
| Email Notification Critical
| 03 Nov, 2022 | US11504333 |
| Issue Notification Mailed Critical
| 02 Nov, 2022 | US11504333 |
| Application Is Considered Ready for Issue Critical
| 21 Oct, 2022 | US11504333 |
| Dispatch to FDC | 21 Oct, 2022 | US11504333 |
| Issue Fee Payment Received Critical
| 18 Oct, 2022 | US11504333 |
Dabrafenib Mesylate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Dabrafenib Mesylate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
